Valbiotis SA (ALVAL.PA)
6.14 €
-0.12 (-1.92%)
Rating:
Recommendation:
-
| Symbol | ALVAL.PA |
|---|---|
| Price | 6.14 € |
| Beta | 0.637 |
| Volume Avg. | 0.01M |
| Market Cap | 60.846M |
| Shares () | - |
| 52 Week Range | 4.01-7.45 |
| 1y Target Est | - |
| DCF Unlevered | ALVAL.PA DCF -> | |
|---|---|---|
| DCF Levered | ALVAL.PA LDCF -> | |
| ROE | -47.12% | Strong Sell |
| ROA | -18.81% | Sell |
| Operating Margin | - | |
| Debt / Equity | 99.66% | Buy |
| P/E | - | |
| P/B | 2.02 | Strong Buy |
About
Download (Excel)Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.